An Indonesian court struck down a legal provision that permitted patent evergreening, a strategy where pharmaceutical companies file new patents for minor changes to existing medicines to delay generic competition. The ruling marks a significant shift in the global debate over access to medicines. The Constitutional Court determined that a two-year-old amendment, which had previously removed a ban on this practice, was unconstitutional. The court found that the original restriction is necessary to balance the rights of patent holders against the broader public interest, particularly public health. The case was brought by several patients and advocacy groups. Patient advocates stated that the decision sends an important message to other countries, encouraging them to challenge similar industry practices.